Osteoclast Precursor Membrane-Coated Nanoparticles Loaded With Abaloparatide Enable Dual Modulation of Osteoclast and Osteoblast Differentiation.

Fu M, Zhu Q, Chen A, Liu X, Sui Y

Applied biochemistry and biotechnology25 Apr 2026

PMID42033613DOI10.1007/s12010-026-05701-1PepBankPUB-42033613

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone14

In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Abaloparatide (Tymlos).

01LabNot a test of Abaloparatide (Tymlos) aloneIn vitro (cells)Mechanism
In cell cultures, both cell types efficiently internalized abaloparatide-loaded membrane-coated nanoparticles.
In plain wordsIn cells, both cell types efficiently absorbed abaloparatide-loaded membrane-coated particles.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableCellular uptake
Study
n: not reported in source
Osteoclast precursor and osteoblast cultures
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
ANPs were spherical (~ 105 nm), exhibited sustained drug release (58% at day 5), and were efficiently internalized by both cell types.
1 context sentence(design, population, supporting numbers)
Summary · context
This study investigated whether abaloparatide-loaded nanoparticles coated with osteoclast precursor cell membranes (ANPs) can modulate the differentiation of both cell types in vitro. ANPs were prepared by incubating abaloparatide with membranes isolated from RAW 264.7 cells.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-4203361303
02LabNot a test of Abaloparatide (Tymlos) aloneIn vitro (cells)Mechanism
In osteoclast precursors, abaloparatide-loaded membrane-coated nanoparticles suppressed RANKL-induced differentiation.
In plain wordsIn cells, abaloparatide-loaded membrane-coated particles suppressed RANKL-induced osteoclast development.
Peptide
Abaloparatide (Tymlos)
Outcome
DecreaseOsteoclast differentiation
Study
n: not reported in source
Osteoclast precursor and osteoblast cultures
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In osteoclast precursors, ANPs suppressed RANKL-induced differentiation, downregulating CTSK, NFATc1, and TRAP without affecting cell viability.
1 context sentence(design, population, supporting numbers)
Summary · context
This study investigated whether abaloparatide-loaded nanoparticles coated with osteoclast precursor cell membranes (ANPs) can modulate the differentiation of both cell types in vitro. ANPs were prepared by incubating abaloparatide with membranes isolated from RAW 264.7 cells.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-4203361304
03LabNot a test of Abaloparatide (Tymlos) aloneIn vitro (cells)Mechanism
In osteoclast precursors, abaloparatide-loaded membrane-coated nanoparticles reduced CTSK expression.
In plain wordsIn cells, abaloparatide-loaded membrane-coated particles reduced CTSK expression.
Peptide
Abaloparatide (Tymlos)
Outcome
DecreaseCTSK expression
Study
n: not reported in source
Osteoclast precursor and osteoblast cultures
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In osteoclast precursors, ANPs suppressed RANKL-induced differentiation, downregulating CTSK, NFATc1, and TRAP without affecting cell viability.
1 context sentence(design, population, supporting numbers)
Summary · context
This study investigated whether abaloparatide-loaded nanoparticles coated with osteoclast precursor cell membranes (ANPs) can modulate the differentiation of both cell types in vitro. ANPs were prepared by incubating abaloparatide with membranes isolated from RAW 264.7 cells.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-4203361305
04LabNot a test of Abaloparatide (Tymlos) aloneIn vitro (cells)Mechanism
In osteoclast precursors, abaloparatide-loaded membrane-coated nanoparticles reduced NFATc1 expression.
In plain wordsIn cells, abaloparatide-loaded membrane-coated particles reduced NFATc1 expression.
Peptide
Abaloparatide (Tymlos)
Outcome
DecreaseNFATc1 expression
Study
n: not reported in source
Osteoclast precursor and osteoblast cultures
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In osteoclast precursors, ANPs suppressed RANKL-induced differentiation, downregulating CTSK, NFATc1, and TRAP without affecting cell viability.
1 context sentence(design, population, supporting numbers)
Summary · context
This study investigated whether abaloparatide-loaded nanoparticles coated with osteoclast precursor cell membranes (ANPs) can modulate the differentiation of both cell types in vitro. ANPs were prepared by incubating abaloparatide with membranes isolated from RAW 264.7 cells.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-4203361306
05LabNot a test of Abaloparatide (Tymlos) aloneIn vitro (cells)Mechanism
In osteoclast precursors, abaloparatide-loaded membrane-coated nanoparticles reduced TRAP expression.
In plain wordsIn cells, abaloparatide-loaded membrane-coated particles reduced TRAP expression.
Peptide
Abaloparatide (Tymlos)
Outcome
DecreaseTRAP expression
Study
n: not reported in source
Osteoclast precursor and osteoblast cultures
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In osteoclast precursors, ANPs suppressed RANKL-induced differentiation, downregulating CTSK, NFATc1, and TRAP without affecting cell viability.
1 context sentence(design, population, supporting numbers)
Summary · context
This study investigated whether abaloparatide-loaded nanoparticles coated with osteoclast precursor cell membranes (ANPs) can modulate the differentiation of both cell types in vitro. ANPs were prepared by incubating abaloparatide with membranes isolated from RAW 264.7 cells.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-4203361307
06LabNot a test of Abaloparatide (Tymlos) aloneIn vitro (cells)Safety outcome
In osteoclast precursors, abaloparatide-loaded membrane-coated nanoparticles did not affect cell viability.
In plain wordsIn cells, abaloparatide-loaded membrane-coated particles did not affect osteoclast precursor survival.
Peptide
Abaloparatide (Tymlos)
Outcome
No significant changeCell viability
Study
n: not reported in source
Osteoclast precursor and osteoblast cultures
Outcome group
Adverse events · Musculoskeletal
Source sentences
Summary
In osteoclast precursors, ANPs suppressed RANKL-induced differentiation, downregulating CTSK, NFATc1, and TRAP without affecting cell viability.
1 context sentence(design, population, supporting numbers)
Summary · context
This study investigated whether abaloparatide-loaded nanoparticles coated with osteoclast precursor cell membranes (ANPs) can modulate the differentiation of both cell types in vitro. ANPs were prepared by incubating abaloparatide with membranes isolated from RAW 264.7 cells.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-4203361308
07LabNot a test of Abaloparatide (Tymlos) aloneIn vitro (cells)Mechanism
In osteoblasts, abaloparatide-loaded membrane-coated nanoparticles enhanced mineralization.
In plain wordsIn cells, abaloparatide-loaded membrane-coated particles increased mineral formation by osteoblasts.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseMineralization
Study
n: not reported in source
Osteoclast precursor and osteoblast cultures
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In osteoblasts, ANPs enhanced mineralization and upregulated Runx2, Osterix, and Osteocalcin.
1 context sentence(design, population, supporting numbers)
Summary · context
This study investigated whether abaloparatide-loaded nanoparticles coated with osteoclast precursor cell membranes (ANPs) can modulate the differentiation of both cell types in vitro. ANPs were prepared by incubating abaloparatide with membranes isolated from RAW 264.7 cells.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-4203361309
08LabNot a test of Abaloparatide (Tymlos) aloneIn vitro (cells)Mechanism
In osteoblasts, abaloparatide-loaded membrane-coated nanoparticles increased Runx2 expression.
In plain wordsIn cells, abaloparatide-loaded membrane-coated particles increased Runx2 expression.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseRunx2 expression
Study
n: not reported in source
Osteoclast precursor and osteoblast cultures
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In osteoblasts, ANPs enhanced mineralization and upregulated Runx2, Osterix, and Osteocalcin.
1 context sentence(design, population, supporting numbers)
Summary · context
This study investigated whether abaloparatide-loaded nanoparticles coated with osteoclast precursor cell membranes (ANPs) can modulate the differentiation of both cell types in vitro. ANPs were prepared by incubating abaloparatide with membranes isolated from RAW 264.7 cells.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-4203361310
09LabNot a test of Abaloparatide (Tymlos) aloneIn vitro (cells)Mechanism
In osteoblasts, abaloparatide-loaded membrane-coated nanoparticles increased Osterix expression.
In plain wordsIn cells, abaloparatide-loaded membrane-coated particles increased Osterix expression.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseOsterix expression
Study
n: not reported in source
Osteoclast precursor and osteoblast cultures
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In osteoblasts, ANPs enhanced mineralization and upregulated Runx2, Osterix, and Osteocalcin.
1 context sentence(design, population, supporting numbers)
Summary · context
This study investigated whether abaloparatide-loaded nanoparticles coated with osteoclast precursor cell membranes (ANPs) can modulate the differentiation of both cell types in vitro. ANPs were prepared by incubating abaloparatide with membranes isolated from RAW 264.7 cells.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-4203361311
10LabNot a test of Abaloparatide (Tymlos) aloneIn vitro (cells)Mechanism
In osteoblasts, abaloparatide-loaded membrane-coated nanoparticles increased Osteocalcin expression.
In plain wordsIn cells, abaloparatide-loaded membrane-coated particles increased Osteocalcin expression.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseOsteocalcin expression
Study
n: not reported in source
Osteoclast precursor and osteoblast cultures
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In osteoblasts, ANPs enhanced mineralization and upregulated Runx2, Osterix, and Osteocalcin.
1 context sentence(design, population, supporting numbers)
Summary · context
This study investigated whether abaloparatide-loaded nanoparticles coated with osteoclast precursor cell membranes (ANPs) can modulate the differentiation of both cell types in vitro. ANPs were prepared by incubating abaloparatide with membranes isolated from RAW 264.7 cells.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-4203361312
11LabNot a test of Abaloparatide (Tymlos) aloneIn vitro (cells)Mechanism
In co-culture, abaloparatide-loaded membrane-coated nanoparticles reduced CTX-I secretion.
In plain wordsIn cells grown together, abaloparatide-loaded membrane-coated particles reduced CTX-I release.
Peptide
Abaloparatide (Tymlos)
Outcome
DecreaseCTX-I secretion
Study
n: not reported in source
Osteoclast precursor and osteoblast cultures
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In co-culture, ANPs reduced CTX-I and increased P1NP secretion, indicating a shift toward bone formation.
1 context sentence(design, population, supporting numbers)
Summary · context
This study investigated whether abaloparatide-loaded nanoparticles coated with osteoclast precursor cell membranes (ANPs) can modulate the differentiation of both cell types in vitro. ANPs were prepared by incubating abaloparatide with membranes isolated from RAW 264.7 cells.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-4203361313
12LabNot a test of Abaloparatide (Tymlos) aloneIn vitro (cells)Mechanism
In co-culture, abaloparatide-loaded membrane-coated nanoparticles increased P1NP secretion.
In plain wordsIn cells grown together, abaloparatide-loaded membrane-coated particles increased P1NP release.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseP1NP secretion
Study
n: not reported in source
Osteoclast precursor and osteoblast cultures
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In co-culture, ANPs reduced CTX-I and increased P1NP secretion, indicating a shift toward bone formation.
1 context sentence(design, population, supporting numbers)
Summary · context
This study investigated whether abaloparatide-loaded nanoparticles coated with osteoclast precursor cell membranes (ANPs) can modulate the differentiation of both cell types in vitro. ANPs were prepared by incubating abaloparatide with membranes isolated from RAW 264.7 cells.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-4203361314
13LabNot a test of Abaloparatide (Tymlos) aloneIn vitro (cell-free)Other
In laboratory characterization, abaloparatide-loaded membrane-coated nanoparticles were spherical and approximately 105 nm.
In plain wordsIn lab tests, the abaloparatide-loaded membrane-coated particles were spherical and approximately 105 nm.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableParticle size
Study
n: not reported in source
Membrane-coated nanoparticle characterization
Outcome group
Formulation, delivery and stability · Pharmacology
Measurements
Particle diameter
105 nm
Approximate particle size
Source sentences
Summary
ANPs were spherical (~ 105 nm), exhibited sustained drug release (58% at day 5), and were efficiently internalized by both cell types.
1 context sentence(design, population, supporting numbers)
Summary · context
This study investigated whether abaloparatide-loaded nanoparticles coated with osteoclast precursor cell membranes (ANPs) can modulate the differentiation of both cell types in vitro. ANPs were prepared by incubating abaloparatide with membranes isolated from RAW 264.7 cells.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-4203361301
14LabNot a test of Abaloparatide (Tymlos) aloneIn vitro (cell-free)Pharmacokinetics
In laboratory characterization, abaloparatide-loaded membrane-coated nanoparticles released 58% of drug at day 5.
In plain wordsIn lab tests, abaloparatide-loaded membrane-coated particles released 58% of drug at day 5.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableDrug release
Study
n: not reported in source
Membrane-coated nanoparticle release assay
Outcome group
Pharmacokinetics · Pharmacology
Measurements
Drug release
58%
Day 5
Source sentences
Summary
ANPs were spherical (~ 105 nm), exhibited sustained drug release (58% at day 5), and were efficiently internalized by both cell types.
1 context sentence(design, population, supporting numbers)
Summary · context
This study investigated whether abaloparatide-loaded nanoparticles coated with osteoclast precursor cell membranes (ANPs) can modulate the differentiation of both cell types in vitro. ANPs were prepared by incubating abaloparatide with membranes isolated from RAW 264.7 cells.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-4203361302

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.